Shots:

• Australian Therapeutic Goods Administration (TGA) Clinical Trial Notification (CTN) scheme is responsible for conducting the NeuLara P-I trial and is being conducted across 200 healthy volunteers assessing PK and safety of US- and EU-sourced Stelara
• NeuClone’s NeuLara is the second biosimilar in pipeline to enter in clinical development and is developed in partnership with Serum Institute of India
• NeuLara is a mAb targeting interleukin-12 and -23 developed to treat patients with plaque psoriasis- psoriatic arthritis- Crohn’s disease- and ulcerative colitis

Click here to­ read full press release/ article | Ref: NeuClone | Image: Twitter